Bapineuzumab

Summary

Bapineuzumab (CHEMBL2108576) is a phase-3 clinical-stage antibody; indicated across 1 condition including alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 1 condition
• Clinical trials: 15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108576
Name	Bapineuzumab
Type	Antibody
Max phase	3

Also known as: 3D-6, AAB-001, Humanized 3D-6 Monoclonal Antibody, Bapineuzumab, HUMANIZED 3D-6 MONOCLONAL ANTIBODY, BAPINEUZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	3	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE3	7
PHASE2	6
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00574132	PHASE3	COMPLETED	Bapineuzumab in Patients With Mild to Moderate Alzheimer’s Disease (ApoE4 Non-Carrier)
NCT00575055	PHASE3	COMPLETED	Bapineuzumab in Patients With Mild to Moderate Alzheimer’s Disease (ApoE4 Carrier)
NCT00667810	PHASE3	TERMINATED	Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
NCT00676143	PHASE3	TERMINATED	Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
NCT00937352	PHASE3	TERMINATED	A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer’s Disease
NCT00996918	PHASE3	TERMINATED	A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
NCT00998764	PHASE3	TERMINATED	A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
NCT00112073	PHASE2	COMPLETED	AAB-001 in Patients With Mild to Moderate Alzheimer’s Disease
NCT00174525	PHASE2	UNKNOWN	Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer’s Disease
NCT00606476	PHASE2	TERMINATED	AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer’s Disease
NCT00663026	PHASE2	COMPLETED	Study Evaluating Bapineuzumab In Alzheimer Disease Subjects
NCT00916617	PHASE2	TERMINATED	Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
NCT01254773	PHASE2	COMPLETED	Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer’s Disease
NCT00397891	PHASE1	COMPLETED	Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease
NCT01658722	Not specified	TERMINATED	Retrieval of Patient Information After Discontinuation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).